These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8622219)

  • 1. Carcinogenicity of lipid-lowering drugs.
    Tobert JA
    JAMA; 1996 May; 275(19):1480-2. PubMed ID: 8622219
    [No Abstract]   [Full Text] [Related]  

  • 2. Carcinogenicity of lipid-lowering drugs.
    Pahor M
    JAMA; 1996 May; 275(19):1480; author reply 1481-2. PubMed ID: 8622218
    [No Abstract]   [Full Text] [Related]  

  • 3. Carcinogenicity of lipid-lowering drugs.
    Illingworth R
    JAMA; 1996 May; 275(19):1479-80; author reply 1481-2. PubMed ID: 8622216
    [No Abstract]   [Full Text] [Related]  

  • 4. Carcinogenicity of lipid-lowering drugs.
    Cattley RC
    JAMA; 1996 May; 275(19):1479; author reply 1481-2. PubMed ID: 8622215
    [No Abstract]   [Full Text] [Related]  

  • 5. Carcinogenicity of lipid-lowering drugs.
    Laws A
    JAMA; 1996 May; 275(19):1480; author reply 1481-2. PubMed ID: 8622217
    [No Abstract]   [Full Text] [Related]  

  • 6. Carcinogenicity of lipid-lowering drugs.
    JAMA; 1996 May; 275(19):1481-2. PubMed ID: 8622220
    [No Abstract]   [Full Text] [Related]  

  • 7. Carcinogenicity of lipid-lowering drugs.
    Newman TB; Hulley SB
    JAMA; 1996 Jan; 275(1):55-60. PubMed ID: 8531288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining patient risks from expanded preventive therapies.
    Tolman KG
    Am J Cardiol; 2000 Jun; 85(12A):15E-9E. PubMed ID: 10858489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint.
    Strom BL
    JAMA; 2004 Dec; 292(21):2643-6. PubMed ID: 15572722
    [No Abstract]   [Full Text] [Related]  

  • 10. Recommendations for Phase IV studies in the development of lipid-lowering drugs.
    Gregg RE
    Am J Cardiol; 1998 Apr; 81(8A):64F-66F. PubMed ID: 9604913
    [No Abstract]   [Full Text] [Related]  

  • 11. Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis".
    Piorkowski JD
    JAMA; 2004 Dec; 292(21):2655-7; discussion 2658-9. PubMed ID: 15572725
    [No Abstract]   [Full Text] [Related]  

  • 12. Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs.
    Psaty BM; Lumley T
    JAMA; 2008 Mar; 299(12):1474-6. PubMed ID: 18364491
    [No Abstract]   [Full Text] [Related]  

  • 13. The challenge of regulating development and approval of drugs with pleiotropic action in cardiovascular disease.
    Temple R
    Am J Cardiol; 1998 Apr; 81(8A):5F-9F. PubMed ID: 9604896
    [No Abstract]   [Full Text] [Related]  

  • 14. [Impact of lipid lowering therapy on liver function].
    Paragh G; Fülöp P
    Orv Hetil; 2009 Jun; 150(26):1205-12. PubMed ID: 19546077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone.
    Jacobson RH; Wang P; Glueck CJ
    JAMA; 1997 Jan 22-29; 277(4):296-7. PubMed ID: 9002485
    [No Abstract]   [Full Text] [Related]  

  • 16. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio.
    De Pinieux G; Chariot P; Ammi-Saïd M; Louarn F; Lejonc JL; Astier A; Jacotot B; Gherardi R
    Br J Clin Pharmacol; 1996 Sep; 42(3):333-7. PubMed ID: 8877024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological profile of SMP-797, a novel acyl-coenzyme a: cholesterol acyltransferase inhibitor with inducible effect on the expression of low-density lipoprotein receptor.
    Ioriya K; Kino K; Horisawa S; Nishimura T; Muraoka M; Noguchi T; Ohashi N
    J Cardiovasc Pharmacol; 2006 Feb; 47(2):322-9. PubMed ID: 16495773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism-based risk assessment of peroxisome proliferating rodent hepatocarcinogens.
    Williams GM; Perrone C
    Ann N Y Acad Sci; 1996 Dec; 804():554-72. PubMed ID: 8993573
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence.
    Cicero AF; Tartagni E; Ertek S
    Expert Opin Biol Ther; 2014 Jun; 14(6):863-8. PubMed ID: 24661068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid-lowering agents and hepatotoxicity.
    Demyen M; Alkhalloufi K; Pyrsopoulos NT
    Clin Liver Dis; 2013 Nov; 17(4):699-714, x. PubMed ID: 24099026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.